Xu et al. reported that the presence of a polymorphism in UGT1A1 was significantly associated with pazopanib-induced hyperbilirubinemia, indicating that isolated unconjugated hyperbilirubinemia was a benign finding associated with Gilbert's syndrome, which did not require discontinuation of drug therapy [37]. Here, UGT1A1 is linked to Hyperbilirubinemia.